文献速递多重用药老年慢病共病管理

多重用药对维生素K拮抗剂患者临床结局的影响

Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists.
PubMed 文献 · J Am Geriatr Soc · 2018-12-11

该前瞻性队列研究基于2011例接受维生素K拮抗剂(苯丙香豆素)的患者,发现多重用药(≥5种药物)患病率为84.1%。多重用药与抗凝质量下降(治疗范围内时间百分比降低)及出血、住院和全因死亡风险升高独立相关,且呈剂量依赖关系。

要点

  • 多重用药(≥5种药物)在维生素K拮抗剂患者中患病率高达84.1%。
  • 多重用药与抗凝治疗质量下降(治疗范围内时间百分比降低)及INR变异性增加相关。
  • ≥9种药物独立增加出血、住院和全因死亡风险,每增加一种药物出血风险增加4%。

核心结论

  • 多重用药影响抗凝治疗质量,并转化为抗凝患者不良事件风险升高。
  • 提示医生应审慎审查此类患者的额外用药,并重视减少多重用药的干预研究。

研究设计与样本

  • 前瞻性队列研究,纳入2011例接受维生素K拮抗剂(苯丙香豆素)的患者,来自前瞻性多中心thrombEVAL研究。
  • 数据来自临床访视、计算机辅助访谈和实验室检测,临床结局信息在3年随访期间获取并经病历验证。

主要发现

  • 多重用药(≥5种药物)患病率为84.1%(n=1691)。
  • 抗凝质量(治疗范围内时间百分比)在5-8种药物组为70.7%、≥9种药物组为64.7%,均低于无多重用药组的73.4%。
  • 多重用药组INR测量变异性显著更高。
  • 出血、住院和全因死亡的累积发生率随用药组别增加而升高,但血栓栓塞事件无此趋势。

关键数值与推荐

  • 多重用药定义为使用5种或以上药物。
  • 抗凝质量以治疗范围内时间百分比评估,无多重用药组73.4%,5-8种药物组70.7%,≥9种药物组64.7%。
  • 每增加一种药物,出血风险增加4%。

临床怎么用

  • 对接受维生素K拮抗剂的多重用药患者,应审慎审查额外用药的必要性。
  • 重视减少多重用药的干预措施,以降低出血、住院和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although polypharmacy is associated with a negative clinical outcome in various settings and commonly observed in patients receiving oral anticoagulation therapy, evidence on the relevance for the clinical outcome of anticoagulated patients is currently limited. The aim of the study was to investigate the effect of polypharmacy on the clinical outcomes among patients taking phenprocoumon. DESIGN: Prospective cohort study. SETTING: Regular medical care. PARTICIPANTS: Information on 2011 individuals receiving vitamin K antagonists was available for analysis from the prospective multicenter thrombEVAL study. MEASUREMENTS: Data were obtained from clinical visits, computer-assisted interviews, and laboratory measurements. Information on clinical outcome was obtained during a 3-year follow-up period and subsequently validated via medical records. RESULTS: The prevalence of polypharmacy (five drugs or more) was 84.1% (n = 1691). Quality of anticoagulation therapy assessed by time in therapeutic range was lower in individuals on five to eight drugs and nine drugs or more (70.7% and 64.7%, respectively) compared with subjects without polypharmacy (73.4%). In addition, a significantly higher variability of international normalized ratio measurements was found in the presence of polypharmacy. The cumulative incidence of bleeding, hospitalization, and all-cause mortality, but not for thromboembolic events, increased across groups of medication. In adjusted Cox regression analysis, polypharmacy is an independent risk factor for bleeding (hazard ratio [HR]≥ 9 drugs vs 1-4 drugs = 1.62; 95% confidence interval [CI] = 1.04-2.52; p = .033); hospitalization (HR≥ 9 drugs vs 1-4 drugs = 1.60; 95% CI = 1.26-2.03; p < .001; and all-cause mortality (HR≥ 9 drugs vs 1-4 drugs = 2.16; 95% CI = 1.43-3.27; p < .001) in a dose-dependent relationship. Per additional drug, bleeding risk was increased by 4%. CONCLUSIONS: Polypharmacy influences the quality of anticoagulation therapy and translates into an elevated risk of adverse events in anticoagulated patients. This suggests that additional medication intake in such patients should be critically reviewed by physicians, and it highlights the importance of initiating investigations aimed at reducing multiple medication intake. J Am Geriatr Soc 67:463-470, 2019.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Eggebrecht L, Nagler M, Göbel S, et al. Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists. J Am Geriatr Soc. 2018. PMID: 30536652. doi:10.1111/jgs.15712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。